SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically me

IMNN

Related stories